TW203007B - - Google Patents

Download PDF

Info

Publication number
TW203007B
TW203007B TW081104335A TW81104335A TW203007B TW 203007 B TW203007 B TW 203007B TW 081104335 A TW081104335 A TW 081104335A TW 81104335 A TW81104335 A TW 81104335A TW 203007 B TW203007 B TW 203007B
Authority
TW
Taiwan
Prior art keywords
insulin
positions
application
treatment
diabetes
Prior art date
Application number
TW081104335A
Other languages
English (en)
Chinese (zh)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of TW203007B publication Critical patent/TW203007B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW081104335A 1991-06-07 1992-06-02 TW203007B (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13646591 1991-06-07

Publications (1)

Publication Number Publication Date
TW203007B true TW203007B (cg-RX-API-DMAC10.html) 1993-04-01

Family

ID=15175749

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081104335A TW203007B (cg-RX-API-DMAC10.html) 1991-06-07 1992-06-02

Country Status (9)

Country Link
US (1) US5480891A (cg-RX-API-DMAC10.html)
EP (1) EP0543018B1 (cg-RX-API-DMAC10.html)
JP (1) JP2608227B2 (cg-RX-API-DMAC10.html)
KR (1) KR0180248B1 (cg-RX-API-DMAC10.html)
CA (1) CA2088582A1 (cg-RX-API-DMAC10.html)
DE (1) DE69207560T2 (cg-RX-API-DMAC10.html)
DK (1) DK0543018T3 (cg-RX-API-DMAC10.html)
TW (1) TW203007B (cg-RX-API-DMAC10.html)
WO (1) WO1992021342A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW227558B (cg-RX-API-DMAC10.html) * 1992-05-14 1994-08-01 Otsuka Pharma Co Ltd
KR100191191B1 (ko) * 1993-10-21 1999-06-15 오쓰까 아끼히꼬 인터루킨-8합성억제의 카르보스티릴 유도체
AU8003194A (en) * 1993-11-05 1995-05-23 Otsuka Pharmaceutical Co., Ltd. Bismuth salt of carbostyril derivatives for the treatment of peptic ulcers
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
CA2259487A1 (en) 1996-07-01 1998-01-08 Margaret Mary Faul Hypoglycemic and hypolipidemic compounds
CA2259431A1 (en) * 1996-07-01 1998-01-08 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
WO2001016111A2 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Hypoglycemic sulfonyl pyrazolones and pyrazolines
US7879877B2 (en) 2003-07-30 2011-02-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for accelerating salivation
TWI340650B (en) * 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
KR101395984B1 (ko) * 2011-10-21 2014-05-16 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
JPS6026797B2 (ja) * 1976-07-12 1985-06-25 大塚製薬株式会社 新規なカルボスチリル誘導体
JPS609511B2 (ja) * 1976-07-16 1985-03-11 大塚製薬株式会社 5−カルボスチリルメタノ−ル誘導体
JPS6037098B2 (ja) * 1978-01-13 1985-08-24 大塚製薬株式会社 5―ホルミルカルボスチリル誘導体
FI80022C (fi) * 1982-07-05 1990-04-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat.
JPS597168A (ja) * 1982-07-05 1984-01-14 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JP2812998B2 (ja) * 1989-08-14 1998-10-22 大塚製薬 株式会社 胃炎治療剤
JP2820739B2 (ja) * 1989-10-28 1998-11-05 大塚製薬株式会社 カルボスチリル誘導体の製造法
JPH07112454A (ja) * 1993-10-19 1995-05-02 Sekisui Chem Co Ltd プラスチック成形品のボス構造

Also Published As

Publication number Publication date
EP0543018A1 (en) 1993-05-26
AU645690B2 (en) 1994-01-20
WO1992021342A1 (en) 1992-12-10
EP0543018B1 (en) 1996-01-10
JP2608227B2 (ja) 1997-05-07
DE69207560T2 (de) 1996-06-27
DE69207560D1 (de) 1996-02-22
JPH05148143A (ja) 1993-06-15
KR0180248B1 (ko) 1999-03-20
DK0543018T3 (da) 1996-02-05
KR930701170A (ko) 1993-06-11
AU1783392A (en) 1993-01-08
EP0543018A4 (en) 1994-06-01
CA2088582A1 (en) 1992-12-08
US5480891A (en) 1996-01-02

Similar Documents

Publication Publication Date Title
TW314466B (cg-RX-API-DMAC10.html)
CN1109542C (zh) 改进的尼古丁锭剂和戒烟治疗的方法
HUP9904026A2 (hu) Sibutraminanalógok alkalmazása diabetes kifejlődésének megelőzésére
CN1171237A (zh) 肠液量调整剂
TW503107B (en) Composition for treatment of insulin resistance syndromes
JP4394686B2 (ja) 唾液分泌促進用医薬組成物およびその使用
EP0543018B1 (en) Antidiabetic agent
CN111956751A (zh) 一种治疗高尿酸血症的药物组合物及其制备方法
JP3982889B2 (ja) イブプロフェン含有医薬製剤
CN1817896A (zh) 槲皮素类化合物及其糖苷的金属配合物及其应用
US4229477A (en) Pharmaceutical compositions containing bromhexine and method of treating diabetic nephropathy therewith
CN1393264A (zh) 黄连素作为胰岛素增敏剂的用途
JPH0354644B2 (cg-RX-API-DMAC10.html)
WO2004032924A1 (fr) Emploi de berberine en tant que sensibilisant insulinique
CN101801373B (zh) 具有抗糖尿病作用的药物组合物
DE69017870T2 (de) Pharmazeutische Zubereitungen, die 3-Oxygermylpropionsäurepolymere enthalten zur Hemmung von Zelldegeneration.
CN118178358B (zh) 一种地喹氯铵口腔贴膜制剂及其制备方法
JP2501201B2 (ja) 感冒薬
JPS63170315A (ja) 6−アリル−2−アミノ−5,6,7,8−テトラヒドロ−4H−チアゾロ〔5,4−d〕アゼピンを有効成分とする成長ホルモン放出剤
JP2007137896A (ja) イブプロフェン含有医薬製剤
CN115804813A (zh) 一种发酵虫草菌粉微球复合液及其制备方法和应用
KR20040063291A (ko) 하수오 추출물의 제조방법과 그 추출물을 함유한 당뇨병관련 질환 치료용 의약 조성물
CN101357174B (zh) 一种治疗糖尿病的药物组合物
Huff BIOLOGICAL INTERACTIONS BETWEEN NOMIFENSINE AND VITAMIN B6, ALPHA METHYL-PARA-TYROSINE, FUSARIC ACID, AND HALOPERIDOL; PROPANTHELINE AND VARIOUS GASTRIC ANTACIDS; DIGOXIN AND ASPIRIN
JPS59137414A (ja) 動脈硬化性疾患防止剤